Melatonin, its metabolites and its synthetic analogs as multi-faceted compounds: Antioxidant, prooxidant and inhibitor of bioactivation reactions

Current Medicinal Chemistry

Volumn 22, Issue 4, 2015, Pages 490-499

  Gurer Orhan, Hande ^a   Suzen, Sibel ^b  

^a EGE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Bioactivation inhibitor; Indole; Melatonin; Prooxidant

Indexed keywords

5 METHOXYINDOLEACETIC ACID; 5 METHOXYTRYPTAMINE; 5 METHOXYTRYPTOPHOL; 6 HYDROXYMELATONIN; 6 HYDROXYMELATONIN GLUCURONIDE; 6 HYDROXYMELATONIN O SULFATE; ANTIOXIDANT; INDOLE; MELATONIN; MELATONIN DERIVATIVE; OXIDIZING AGENT; UNCLASSIFIED DRUG; CARCINOGEN; INDOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOSYNTHESIS; CARCINOGENESIS; CELL PROTECTION; CHEMICAL CARCINOGENESIS; HORMONE ACTION; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; METABOLITE; NEUROPROTECTION; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLIC ACTIVATION; METABOLISM;

ACTIVATION, METABOLIC; ANIMALS; ANTIOXIDANTS; CARCINOGENS; HUMANS; INDOLES; MELATONIN; OXIDANTS;

EID: 84928818440     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141215095259     Document Type: Article

References (114)

1. Suzen, S.; Cihaner, S.S.; Coban, T. Synthesis and comparison of antioxidant properties of indole-based melatonin analogue indole amino Acid derivatives. Chem. Biol. Drug Des., 2012, 79(1), 76-83.
2. Shirinzadeh, H.; Gumustas, M.; Suzen, S.; Ozden, S.; Ozkan S.A. Synthesis and Investigation of Electrochemical Behaviour of NMethylindole-3-Carboxaldehyde Izonicotinoyl Hydrazone. Molecules, 2010, 15(4), 2187-2202.
3. Tan, D.X.; Chen, L.D.; Poeggeler, B.; Manchester, L.C.; Reiter, R.J. Melatonin: A potent endogenous hydroxyl radical scavenger. Endocr. J., 1993, 1, 57-60.
4. Tan, D-X.; Reiter, R. J.; Manchester, L. C.; Yan, M-T.; El-Sawi, M.; Sainz, R. M.; Mayo, J. C.; Kohen, R.; Allegra, M.; Hardeland, R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem., 2002, 2, 181-197.
5. Lemoine, P.; Zisapel, N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin. Pharmacother., 2012, 13, 895-905.
6. Beyer, C.E.; Steketee, J.D.; Saphier, D. Antioxidant properties of melatonin-an emerging mystery. Biochem. Pharm., 1998, 56, 1265-1272.
7. Thomas, B.; Mohanakumar, K.P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J. Pineal Res., 2004, 36, 25-32.
8. Chen, Z.; Chua, C.C.; Gao, J.; Hamdy, R.C.; Chua, B.H. Protective effect of melatonin on myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2003, 284, H1618-H1624.
9. Reiter, R.J.; Tan, D.X.; Osuna, C.; Gitto, E. Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci., 2000, 7, 4440-4458.
10. Ma, X.; Idle, J.R.; Krausz, K.W.; Tan, D.X.; Ceraulo, L.; Gonzalez, F.J. Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. J. Pineal Res., 2006, 40(4), 343-349.
11. Sewerynek, E.; Reiter, R.J.; Melchiorri, D.; Ortiz, G.G.; Lewinski, A. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology, 1996, 43, 898-905.
12. Kunduzova, O.R.; Escourrou, G.; Seguelas, M.H.; Delagrange, P.; De La Farge, F.; Cambon, C.; Parini, A. Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion. FASEB J., 2003, 17, 872-874.
13. Wakatsuki, A.; Okatani, Y.; Shinohara, K.; Ikenoue, N.; Fukaya, T. Melatonin protects against ischemia/reperfusion-induced oxidative damage to mitochondria in fetal rat brain. J. Pineal Res., 2001, 31, 167-172.
14. Ozdemir, D.; Tugyan, K.; Uysal, N.; Sonmez, U.; Sonmez, A.; Acikgoz, O.; Ozdemir, N.; Duman, M.; Ozkan, H. Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. Neurosci. Lett., 2005, 385, 234-239.
15. Lopez, P.M.; Finana, I.T.; de Agueda, M.C.; Sánchez, E.C.; Muñoz, M.C.; Alvarez, J.P.; De La Torre, Lozano, E.J. Protective effect of melatonin against oxidative stress induced by ligature of extra-hepatic biliary duct in rats: comparison with the effect of Sadenosyl-L-methionine. J. Pineal Res., 2000, 28, 143-149.
16. El-Sokkary, G.H.; Omar, H.M.; Hassanein, A.F.; Cuzzocrea, S.; Reiter, R.J. Melatonin reduces oxidative damage and increases survival of mice infected with Schistosoma mansoni. Free Radic. Biol. Med., 2002, 32, 319-332.
17. Ghosh, D.; Mitra, M.; Firdaus, S.B.; Ghosh, A.K.; Chattopadhyay, A.; Pattari, S.K.; Bandyopadhyay, D. Melatonin Protects Against Lead-Induced Cardio Toxicity: Involvement of Antioxidant Mechanism. Int. J. Pharm. Pharm. Sci., 2013, 5(3), 806-813.
18. Bozkaya, P.; Dogan, B.; Suzen, S.; Nebioglu D.; Ozkan S.A. Determination and investigation of electrochemical behaviour of 2-phenylindole derivatives: discussion on possible mechanistic pathways. Can. J. Anal. Sci. Spec., 2006, 51, 125-139.
19. Suzen, S.; Demircigil, T.; Buyukbingol, E.; Ozkan, S.A. Electroanalitical Evaluation and Determination of 5-(3'-indolyl)-2-thiohydantoin Derivatives by Voltammetric studies: possible relevance to in vitro metabolism. New J. Chem., 2003, 27, 1007-1011.
20. Suzen, S., Ate-Alagoz, Z.; Demircigil, T.; Ozkan, S.A. Synthesis and Analytical Evaluation by Voltammetric Studies of Some New Indole-3-propionic acid Derivatives. Farmaco, 2001, 56, 835-840.
21. Suzen, S.; Bozkaya, P.; Coban,T.; Nebioglu, D. Investigation of in vitro antioxidant behaviour of some 2-phenylindole derivatives: discussion on possible antioxidant mechanisms and comparison with melatonin. J. Enzyme Inh. Med. Chem., 2006, 21(4), 405-411.
22. Karaaslan, C.; Kadri, H.; Coban, T.; Suzen, S.; Westwell, A.D. Synthesis and antioxidant properties of substituted 2-phenyl-1Hindoles. Bioorg. Med. Chem. Lett., 2013, 23(9), 2671-2674.
23. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Qi, W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: A review of the evidence. Cell. Biochem. Biophys., 2001, 34(2), 237-256.
24. Suzen, S. Recent developments of melatonin related antioxidant compounds. Comb. Chem. High Throughput Screen., 2006, 9, 409-419.
25. Suzen, S. Topics in heterocyclic chemistry, bioactive heterocycles V. In: Khan M.T.H., editor. Antioxidant Activities of Synthetic Indole Derivatives and Possible Activity Mechanisms, Vol 11. Berlin, Heidelberg: Spinger-Verlag; 2007, p. 145-178.
26. Hardeland, R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J. Exp. Integr. Med., 2011, 1(2), 67-81.
27. Gurkok, G.; Coban, T.; Suzen, T. Melatonin analogue new indole hydrazide/hydrazone derivatives with antioxidant behavior: synthesis and structure-activity relationships. J. Enzyme Inhibit. Med. Chem., 2009, 24, 506-515.
28. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.M.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature's most versatile biological signal? FEBS J., 2006, 273, 2813-2838.
29. Bubenik, G.A. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci., 2002, 47, 2336-2348.
30. Claustrat, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev., 2005, 9, 11-24.
31. Ma, X.; Idle, J.R.; Krausz, K.W.; Gonzalez, F.J. Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos., 2005, 33, 489-494.
32. Chowdhury, I.; Maitra, S.K. In: Melatonin in the promotion of health; Watson RR, Ed.; CRC Press: 2nd ed., 2012 pp 12-13.
33. Hardeland, R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine, 2005, 27, 119-130.
34. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Tamura, H.; Reiter, R.J. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: Hypothesis and significance. J. Pineal. Res., 2007, 43, 317-320.
35. Ma, X.; Chen, C.; Krausz, K.W.; Idle, J.R.; Gonzalez, F.J. A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology, 2008, 149, 1869-1879.
36. Hardeland, R.; Pandi-Perumal, S.R.; Cardinali, D.P. Melatonin. Int. J. Biochem. Cell Biol., 2006, 38(3), 313-316.
37. Morceli, G.; Honorio-França, A.C.; Fagundes, D.L.G.; Calderon, I.M.P.; França, E.L. Antioxidant Effect of Melatonin on the Functional Activity of Colostral Phagocytes in Diabetic Women, 2013, 8, e56915.
38. Zhou, J.; Zhang, S.; Zhao, X.; Wei, T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid--1-42. J. Pineal Res., 2008, 45, 157-165.
39. Leon, J.; Escames, G.; Rodriguez, M.I.; Lopez, L.C.; Tapias, V.; Entrena, A.; Camacho, E.; Carrion, M.D.; Gallo, M.A.; Espinosa, A.; Tan, D.X.; Reiter, R.J.; Acuna-Castroviejo, D. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J. Neurochem., 2006, 98, 2023-2033.
40. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Qi, W.B.; Karbownik, M.; Calvo, J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signal. Recep., 2000, 9, 137-159.
41. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007, 42, 28-42.
42. Galano, A.; Tan, D.X.; Reiter, R.J. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal Res., 2013, 54(3), 245-257.
43. Hirata, F.; Hayaishi, O.; Tokuyama, T.; Seno, S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem., 1974, 249, 1311-1313.
44. Tan, D.X.; Manchester, L.C.; Burkhardt, S.; Sainz, R.M.; Mayo, J.C.; Kohen, R.; Shohami, E.; Huo, Y.S.; Hardeland, R.; Reiter, R.J. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J., 2001, 15, 2294-2296.
45. Schaefer, M.; Hardeland, R. The melatonin metabolite N1-acetyl-5-methoxykynuramine is a potent singlet oxygen scavenger. J. Pineal Res., 2009, 46, 49-52.
46. Kuesel, J.T.; Hardeland, R.; Pfoertner, H.; Aeckerle, N. Reactions of the melatonin metabolite N1-acetyl-5-methoxykynuramine with carbamoyl phosphate and related compounds. J. Pineal Res., 2010, 48, 47-54.
47. Hara, M.; Iigo, M.; Ohtani-Kaneko, R.; Nakamura, N.; Suzuki, T.; Reiter, R.J.; Hirata, K. Administration of melatonin and related indoles prevents exercise-induced cellular oxidative changes in rats. Biol. Signals, 1997, 6, 90-100.
48. Dellegar, S.M.; Murphy, S.A.; Bourne, A.E.; Di Cesare, J.C.; Purser, G.H. Identification of the factors affecting the rate of deactivation of hypochlorous acid by melatonin. Biochem. Biophys. Res. Commun., 1999, 257, 431-439.
49. Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Plummer, B.F.; Hardies, L.J.; Weintraub, S.T.; Vijayalaxmi, Shepherd, A.M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun., 1998, 253, 614-620.
50. Peyrot, F.; Martin, M.T.; Migault, J.; Ducrocq, C. Reactivity of peroxynitrite with melatonin as a function of pH and CO2 content. Eur. J. Org. Chem., 2002, 321, 1-10.
51. Ressmeyer, A.R.; Mayo, J.C.; Zelosko, V.; Sáinz, R.M.; Tan, D.X.; Poeggeler, B.; Antolín, I.; Zsizsik, B.K.; Reiter, R.J.; Hardeland, R. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox. Rep., 2003, 8, 205-213.
52. Entrena, A.; Camacho, M.E.; Carrion, M.D.; López-Cara, L.C.; Velasco, G.; León, J.; Escames, G.; Acuña-Castroviejo, D.; Tapias, V.; Gallo, M.A.; Vivó, A.; Espinosa, A. Kynurenamines as neural nitric oxide synthase inhibitors. J. Med. Chem., 2005, 48, 8174-8181.
53. Hardeland, R. Melatonin Metabolism in the Central Nervous System. Curr. Neuropharmacol., 2010, 8, 168-181.
54. Onuki, J.; Almeida, E.A.; Medeiros, M.H.; Di Mascio, P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J. Pineal Res., 2005, 38, 107-115.
55. Reiter, R.J.; Tan, D-X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Koppisepi, S. Medical implications of melatonin: receptormediated and receptor-independent actions. Adv. Med. Sci., 2007, 52, 11-28.
56. Samantaray, S.; Das, A.; Thakore, N.P.; Matzelle, D.D.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Therapeutic potential of melatonin in traumatic central nervous system injury. J. Pineal Res., 2009, 47, 134-142.
57. Wang, X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther., 2009, 15, 345-357.
58. Matsubara, E.; Bryant-Thomas, T.; Pacheco, Q.J.; Henry, T.L.; Poeggeler, B.; Herbert, D.; Cruz-Sanchez, F.; Chyan, Y-J.; Smith, M.A.; Perry, G.; Shoji, M.; Abe, K.; Leone, A.; Grundke-Ikbal, I.; Wilson, G.L.; Ghiso, J.; Williams, C.; Refolo, L.M.; Pappolla, M.A.; Chain, D.G.; Neria, E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem., 2003, 85, 1101-1108.
59. Silva, S.O.; Ximenes, V.F.; Livramento, J.A.; Catalani, L.H.; Campa, A. High concentrations of the melatonin metabolite, N1-acetyl-N2-formyl-5-methoxykynuramine, in cerebrospinal fluid of patients with meningitis: A possible immunomodulatory mechanism. J. Pineal Res., 2005, 39, 302-306.
60. Hardeland, R. Melatonin, mitochondrial electron flux and leakage: recent findings and resolution of contradictory results. Adv. Stud. Biol., 2009, 1, 207-230.
61. Hardeland, R. Neuroprotection by radical avoidance: search for suitable agents. Molecules, 2009, 14, 5054-5102.
62. Chan, T.Y.; Tang, P.L. Characterization of the antioxidant effects of melatonin and related indoleamines in vitro. J. Pineal Res., 1996, 20(4), 187-191.
63. Suzen, S. Melatonin and synthetic analogs as antioxidants. Curr. Drug Deliv., 2013, 10(1), 71-75.
64. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Manchester, L.C. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev. Med. Chem., 2013, 13(3), 373-384.
65. Sewerynek, E.; Wiktorska, J.A.; Stuss, M. 6-methoxytryptophol reduces lipopolysaccharide-induced lipid peroxidation in vitro more effectively than melatonin. J. Physiol. Pharmacol., 2011, 62(6), 677-683.
66. Ressmeyer, A.R.; Mayo, J.C.; Zelosko, V.; Sáinz, R.M.; Tan, D.X.; Poeggeler, B.; Antolín, I.; Zsizsik, B.K.; Reiter, R.J.; Hardeland, R. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox. Rep., 2003, 8(4), 205-213.
67. Timbrell, J. Principles of Biochemical Toxicology, 4th ed.; Informa: New York, 2009.
68. Rickard, J.; Brodie, M.E. Correlation of blood and brain levels of the neurotoxic pyrethroid deltamethrin with the onset of symptoms in rats. Pesticide Biochem. Physiol., 1985, 23, 143-156.
69. Romero, A.; Ramos, E.; Castellano, V.; Martínez, M.A.; Ares, I.; Martínez, M.; Martínez-Larrañaga, M.R.; Anadón, A. Cytotoxicity induced by deltamethrin and its metabolites in SH-SY5Y cells can be differentially prevented by selected antioxidants. Toxicol. In vitro, 2012, 26, 823-830.
70. Samantaray, S.; Sribnick, E.A.; Das, A.; Knaryan, V.H.; Matzelle, D.D.; Yallapragada, A.V.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J. Pineal Res., 2008, 44, 348-357.
71. Samantaray, S.; Das, A.; Thakore, N.P.; Matzelle, D.D.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Therapeutic potential of melatonin in traumatic central nervous system injury. J. Pineal Res., 2009, 47, 134-142.
72. Herraiz, T.; Guillén, H. Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors. Food Chem. Toxicol., 2011, 49, 1773-1781.
73. Adams, J.J.D.; Klaidman, L.K.; Leung, A.C. MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes Free Radic. Biol. Med., 1993, 15, 181-186.
74. Borah, A.; Mohanakumar, K.P., Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J. Pineal Res., 2009, 47, 293-300.
75. Chen, L.J.; Gao, Y.Q.; Li, X.J.; Shen, D.H.; Sun, F.Y. Melatonin protects against MPTP/MPP+-induced mitochondrial DNA oxidative damage in vivo and in vitro. J. Pineal Res., 2005, 39, 34-42.
76. Cerutti, P.; Ghosh, R.; Oya, Y.; Amstad, P. The role of the cellular antioxidant defense in oxidant carcinogenesis. Environ. Health Perspect., 1994, 102 (Suppl. 10), 123-129.
77. Karbownik, M.; Lewinski, A.; Reiter, R.J. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int. J. Biochem.Cell Biol., 2001, 33, 735-753.
78. Karbownik, M.; Reiter, R.J.; Qi, W.; Garcia, J.J.; Tan, D.X.; Manchester, L.C.; Vijayalaxmi. Protective effects of melatonin against oxidation of guanine bases in DNA and decreased microsomal membrane fluidity in rat liver induced by whole body ionizing radiation. Mol. Cell Biochem., 2000, 211, 137-144.
79. Vijayalaxmi, Reiter, R.J.; Tan, D.X.; Herman, T.S.; Thomas, C.R. Jr. Melatonin as a radioprotective agent: A review. Int J. Radiat. Oncol. Biol. Phys., 2004, 59, 639-653.
80. Sánchez-Sánchez, A.M.; Martín, V.; García-Santos, G.; Rodríguez-Blanco, J.; Casado-Zapico, S.; Suarez-Garnacho, S.; Antolín, I.; Rodriguez, C. Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells. Free Radic. Res., 2011, 45, 1333-1341.
81. Crespo, E.; Macías, M.; Pozo, D.; Escames, G.; Martín, M.; Vives, F.; Guerrero, J.M.; Acuña-Castroviejo, D. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and pre vents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J., 1999, 13, 1537-1546.
82. Di Bella, G.; Mascia, F.; Gualano, L.; Di Bella, L. Melatonin anticancer effects: Review. Int. J. Mol. Sci., 2013, 14, 2410-2430.
83. Chowdhury, I.; Sengupta, A.; Maitra, S.K. Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human. Indian J. Biochem. Biophys., 2008, 45, 289-304.
84. Eaton, D.L.; Gallagher, E.P. In: Comprehensive Toxicology: Vol 1-General Overview of Toxicology; 2 nd ed. Watson RR, Ed.; CRC Press; 2010; pp 16-17.
85. Liu, L.; Xu, Y.; Reiter, R.J. Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. Bone, 2013, 55(2), 432-438.
86. Paredes, S.D.; Korkmaz, A.; Manchester, L.C.; Dun-Xian, T.; Russel, J.R. Phytomelatonin: A review. J. Exp. Bot., 2009, 60, 57-69.
87. Tamarkin, L.; Cohen, M.; Roselle, D.; Reichert, C.; Lippman, M.; Chabner, B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat. Cancer Res., 1981, 41, 4432-4436.
88. Cos, S.; Gonzalez, A.; Guezmes, A.; Mediavilla, M.D.; Martínez-Campa, C.; Alonso-González, C.; Sánchez-Barceló, E.J. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer, 2006, 118, 274-278.
89. Kothari, L.; Subramanian, A. A possible modulatory influence of melatonin on representative phase I and II drug metabolizing enzymes in 9, 10-dimethyl-1,2-benzanthracene induced rat mammary tumorigenesis. Anticancer Drugs, 1992, 3, 623-628.
90. Ioannides, C.; Lewis, D.F.V. Cytochromes P450 in the bioactivation of chemicals. Curr. Top. Med. Chem., 2004, 4, 1767-1788.
91. Chang, T.K.; Chen.; Yang, G.; Yeung, E.Y. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J. Pineal Res., 2010, 48(1), 55-64.
92. Yeleswaram, K.; Vachharajani, N.; Santone, K. Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications. J. Pineal Res., 1999, 26, 190-191.
93. De Salvia, R.; Fiore, M:; Aglitti, T:; Festa, F.; Ricordy, R.; Cozzi, R. Inhibitory action of melatonin on H2O2-and cyclophosphamide-induced DNA damage. Mutagenesis, 1999, 14(1), 107-112.
94. Le Blanc, G.A.; Waxman, D.J. Mechanisms of cyclophosphamide action on hepatic P450 expression. Cancer Res., 1990, 50, 5720-5726.
95. Ross, D.; Beall, H.D.; Traver, R.D.; Gustafson, D.L. Enzymology of bioreductive drug activation. Br. J. Cancer Suppl., 1996, 27, S1-S8.
96. Cummings, J.; Spanswick, V.J.; Tomasz, M.; Smyth, J.F. Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Biochem. Pharmacol., 1998, 56, 405-414.
97. Ortega-Gutiérrez, S.; López-Vicente, M.; Lostalé, F.; Fuentes-Broto, L.; Martínez-Ballarín, E.; García, J.J. Protective effect of melatonin against mitomycin C-induced genotoxic damage in peripheral blood of rats. J. Biomed. Biotechnol., 2009, 2009, 791432.
98. Ossenia, R.A.; Rata, P.; Bogdan, A.; Warneta, J.M.; Touitou, Y. Evidence of prooxidant and antioxidant action of melatonin on human liver cell line HepG2. Life Sci., 2000, 68, 387-399.
99. Barsacchi, R.; Kusmic, C.; Damiani, E.; Carloni, P.; Greci, L.; Donato, L. Vitamin E consumption induced by oxidative stress in red blood cells is enhanced by melatonin and reduced by Nacetylserotonin. Free Radic. Biol Med., 1998, 24, 1187-1192.
100. Medina-Navarro, R.; Duran-Reyes, G.; Hicks, J.J. Prooxidating properties of melatonin in the in vitro interaction with the singlet oxygen. Endoc. Res., 1999, 25, 263-280.
101. Wölfler, A.; Caluba, H.C.; Abuja, P.M.; Dohr, G.; Schauenstein, G.; Liebmann, P.M. Prooxidant activity of melatonin promotes fasinduced cell death in human leukemic Jurkat cells. FEBS Lett., 2001, 502, 127-131.
102. Christofanon, S.; Uguccioni, F.; Cerella, C.; Radogna, F.; Dicato, M.; Ghibelli, L.; Diederich, M. Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-KB activation. Ann. N. Y. Acad. Sci., 2009, 1171, 472-478.
103. Reiter, R.J. Melatonin: That ubiquitously acting pineal hormone, News Physiol. Sci., 1991, 6, 223-227.
104. Costa, E.J.X.; Lopes, R.H.; Lamy-Freund, M.T. Solubility of pure bilayers to melatonin J. Pineal Res., 1995, 19, 123-126.
105. Shida, C.S.; Castrucci, A.M.L.; Lamy-Freund, M.T. High melatonin solubility in aqueous media, J. Pineal Res., 1994, 16, 198-201.
106. Sanchez-Barcelo, E.J.; Martinez-Campa C.M.; Mediavilla, M.D.; Gonzalez, A.; Alonso-Gonzalez, C.; Cos, S. Melatonin and melatoninergic drugs as therapeutic agents: Ramelteon and agomelatine, the two most promising melatonin receptor agonists. Recent Pat. Endocr. Metab. Immune Drug Discov., 2007, 1, 142-151.
107. Suzen, S.; Tekiner-Gulbas, B.; Shirinzadeh, H.; Uslu, D.; Gurer-Orhan, H.; Gumustas, M.; Aysil Ozkan, S.Antioxidant activity of indole-based melatonin analogues in erythrocytes and their voltammetric characterization. J. Enzym Inh. Med. Chem., 2013, 28, 1143-1155.
108. Ylmaz, A.D.; Coban, T.; Suzen, S.J. Synthesis and antioxidant activity evaluations of melatonin-based analogue indole-hydrazide/hydrazone derivatives. Enzyme Inhib. Med. Chem., 2012, 27, 428-436.
109. Ates-Alagoz, Z.; Coban, T.; Suzen, S. A Comparative Study: Evaluation of Antioxidant Activity of Melatonin and Some Indole Derivatives. Med. Chem. Res., 2005, 14, 169-179.-
110. Poeggeler, B.; Thuermann, S.; Dose, A.; Schoenke, M.; Burkhardt, S.; Hardeland, R. Melatonin's unique radical scavenging properties-roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res., 2002, 33(1), 20-30.
111. Perez-Reyes, E.; Mason, R.P. Characterization of the structure and reactions of free radicals from serotonin and related indoles. J. Biol. Chem., 1981, 256, 2427-2432.
112. Reiter, R.J.; Tan, D.X.; Jou, M.J.; Korkmaz, A.; Manchester, L.C.; Paredes, S.D. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro. Endocrinol. Lett., 2008, 29(4), 391-398.
113. Reiter, R.J.; Acuña-Castroviejo, D.; Tan, D.X.; Burkhardt, S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann. N. Y. Acad. Sci., 2001, 939, 200-215.
114. Reiter, R.J.; Tan, D.X.; Mayo, J.C.; Sainz, R.M.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim. Pol., 2003, 50(4), 1129-1146